Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial.
Junyang LuJiadi XingLu ZangChenghai ZhangLai XuGuannan ZhangZirui HeYueming SunYifei FengXiaohui DuShidong HuPan ChiYing HuangZi-Qiang WangMing ZhongAiwen WuAnlong ZhuFei LiJianmin XuLiang KangJian SuoHaijun DengYingjiang YeChengcheng LiuTao XuYue-Lun ZhangZhongtao ZhangMinhua ZhengXiangqian SuYi Xiaonull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
This trial failed to find evidence of superior DFS outcome for CME compared with standard D2 lymph node dissection in primary surgical excision of right-sided colon cancer. Standard D2 dissection should be the routine procedure for these patients. CME should only be considered in patients with obvious mesocolic lymph node involvement.
Keyphrases
- phase iii
- lymph node
- open label
- clinical trial
- phase ii
- double blind
- placebo controlled
- sentinel lymph node
- end stage renal disease
- newly diagnosed
- study protocol
- ejection fraction
- early stage
- neoadjuvant chemotherapy
- peritoneal dialysis
- clinical practice
- randomized controlled trial
- rectal cancer
- lymph node metastasis
- squamous cell carcinoma
- radiation therapy
- locally advanced